Clinical TrialsSearch results
Number of results: 1203
Not yet recruiting
- A Study of JNJ-79635322 in Participants with Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
- "Relapsed or Refractory Multiple Myeloma Previously Treated Amyloid Light-chain (AL) Amyloidosis"
- Fujikawa Ei
- 2024-06-21
Recruiting
- A Trial to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety and Tolerability of Zerlasiran in Japanese Subjects With Elevated Serum Lipoprotein(a)
- Japanese subjects with elevated Lp(a)
- Fok Henry
- 2024-06-18
Recruiting
- Parallel-group, placebo-controlled study to evaluate the safety, tolerability, and efficacy of repeated intravenous administration of S-005151 to patients with ischemic cardiomyopathy undergoing coronary artery bypass surgery (Phase I/II)
- Ischemic cardiomyopathy
- Shigeru Miyagawa
- 2024-06-13
Recruiting
- Perioperative changes in QT interval of the electrocardiogram in shoulder arthroplasty
- Patients scheduled for shoulder arthroplasty
- Hori Kotaro
- 2024-06-11
Recruiting
- HERMES study
- Breast cancer
- Mukai Hirofumi
- 2024-06-11
Recruiting
- Clinical trial for the safety and efficacy of MEL-01 soft contact lens
- Patients with refractive errors who have been determined to be eligible for soft contact lenses
- Nakamura Kikue
- 2024-06-10
Recruiting
- A Multicenter Retrospective Observational Study to Investigate the Epidemiology and Recurrence and Prognosis in Patients Undergoing Surgery for Lung Adenocarcinoma Harboring ALK Rearrangement
- Lung adenocarcinoma
- Tsutani Yasuhiro
- 2024-06-10
Recruiting
- Efficacy and safety of the anti-TNF multivalent NANOBODY compound ozoralizumab in RA patients with high titers of rheumatoid factor (OHZORA High study)
- Rheumatoid arthritis
- Hashimoto Motomu
- 2024-06-07
Recruiting
- A Phase 2 Study of an Anti-MTBR Tau Monoclonal Antibody in Participants with Early Alzheimer's Disease
- Early Alzheimer's disease
- Kahl Anja
- 2024-06-07
Recruiting
- A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD-L1 high NSCLC
- Non-small-cell lung cancer
- Ishibashi Hideyasu
- 2024-06-04